Skip to main content

OUR RESPONSIBILITY

Hear our LGBTQ+ Voices

Everyone can be their true selves at Sanofi

ESG Investor Event

July 5, 2022

We invite investors and analysts to participate in our ESG Investor Event being held live in Paris (and webcast) on Tuesday, July 5, 2022 at 2:00pm CET

Exciting next steps in our fight against Covid-19

VACCINES

We are testing different formulations of our recombinant protein adjuvanted vaccine to develop a formulation that could help answer current vaccination needs

Our Integrated Report 2021

ABOUT US

We chase the miracles of science to improve people’s lives and to transform the practice of medicine

Our response to the situation in Ukraine

May 20, 2022

Information and updates on how our company is responding as the situation in Ukraine evolves

Our Latest News

Media Update: Patient enrollment of phase III tolebrutinib trials paused in the U.S.

Press Release: Nexviadyme® (avalglucosidase alfa) approved by European Commission as a potential new standard of care for the treatment of Pompe Disease

Press Release: Xenpozyme® (olipudase alfa) approved by European Commission as first and only treatment for ASMD

Availability of the Q2 2022 Memorandum for modelling purposes

Press Release: Sanofi-GSK first to report a successful efficacy study against Omicron with COVID-19 Beta-containing vaccine

All Press Releases

On Twitter

Build Your Career with Sanofi

You'll be surprised what you can achieve at Sanofi. Discover your future here.

OUR RECRUITMENT PROCESS

SEE ALL OPEN JOBS

SIGN UP FOR JOB ALERTS

You are about to leave sanofi.com

If you wish to continue to this external website, click Proceed.

It is provided for information only. Sanofi assumes no responsibility for the information presented on this website.

PROCEED